Inclusion Criteria (All):

          -  Written informed consent must

          -  Patient has histologically and/or cytologically confirmed malignancies:

        Phase I:

        • Patients with advanced or metastatic solid tumors who have failed at least one prior line
        of systemic antineoplastic therapy in the advanced setting without a standard of care
        treatment option available;

        Phase II:

          -  Advanced or metastatic pancreatic adenocarcinoma who have failed at least one prior
             systemic antineoplastic therapies in the advanced setting

          -  Advanced or metastatic KRAS-mutant CRC who have failed at least two prior systemic
             antineoplastic therapies in the advanced setting without a standard of care treatment
             option available. Testing for KRAS mutation in patients with CRC using locally
             approved diagnostic kit will be used for eligibility.

          -  Phase II only: patient must have measurable disease

          -  Patient has an ECOG performance status 0 or 1.

          -  Patient has adequate bone marrow and organ function

          -  Patient must have specified laboratory values within normal limits or corrected to
             within normal limits with supplements before the first dose of study medication on
             Cycle 1 Day 1:

          -  Standard 12-lead ECG values defined

        Exclusion Criteria:

        Phase II only:

        • Patient has received prior treatment with a MEK inhibitor or a CDK4/6 inhibitor.

        Phase I and Phase II:

          -  Patient with a known hypersensitivity to the study drugs or any of the excipients of
             ribociclib or trametinib.

          -  Patient is concurrently using other anti-cancer therapy.

          -  Patient has received radiotherapy ≤ 4 weeks or limited field radiation for palliation
             ≤ 2 weeks prior to Cycle 1 Day 1

          -  Patient has received local therapy to liver ≤ 3 months of C1D1

          -  History of liver disease as follow:

          -  Cirrhosis

          -  Autoimmune hepatitis

          -  Active viral hepatitis

          -  Portal hypertension

          -  Drug induced liver steatosis

          -  Prior systemic anti-cancer treatment within 28 days prior to Cycle 1 Day 1

          -  Prior therapy with anthracyclines at cumulative doses of 450 mg/ m2 or more for
             doxorubicin or 900 mg/m2 or more for epirubicin.

          -  Patient is currently receiving warfarin or other coumadin derived anti-coagulant

          -  Patient has a history of deep venin thrombosis or pulmonary embolism within 6 months
             of screening.

          -  Patient has a concurrent malignancy or malignancy within 3 years prior to Cycle 1 Day
             1, with the exception of adequately treated basal or squamous cell carcinoma or
             curatively resected cervical cancer.

          -  Patients with central nervous system (CNS) involvement

          -  Patient has impairment of GI function or GI disease that may significantly alter the
             absorption of the study drugs

          -  History of interstitial lung disease or pneumonitis.

          -  Clinically significant, uncontrolled heart disease and/or cardiac repolarization
             abnormality

          -  Patient is currently receiving any strong inducers or inhibitors of CYP3A4/5 and/or
             Substances that have a narrow therapeutic window and are predominantly metabolized
             through CYP3A4/5 and cannot be discontinued 7 days prior to Cycle 1 Day 1:

          -  Patient is currently receiving or has received systemic corticosteroids ≤ 2 weeks
             prior to starting study drug, or who have not fully recovered from side effects of
             such treatment.

          -  History of retinal vein occlusion (RVO)

        Other protocol-defined inclusion/exclusion criteria may apply.